CYTONET SUBMITS EUROPEAN APPROVAL APPLICATION FOR LIVER CELL THERAPY TO TREAT UREA CYCLE DISORDERS IN CHILDREN
Weinheim/Germany (ots) - International biotechnology firm Cytonet announced today that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval for its liver cell therapy for the treatment of Urea Cycle Disorders (UCD) in children. UCD is a life-threatening ...
more